22
Participants
Start Date
February 22, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Rituximab
Dose level 1:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks Expansion:Determined by the result of the dose escalation phase
Shang-Ju Wu, Taipei
National Taiwan University Hospital
OTHER
National Cheng-Kung University Hospital
OTHER
China Medical University Hospital
OTHER
Chang Gung Memorial Hospital
OTHER
National Health Research Institutes, Taiwan
OTHER